Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides

Curr Opin Pharmacol. 2004 Apr;4(2):139-46. doi: 10.1016/j.coph.2003.10.008.

Abstract

Molecular therapy is emerging as a potential strategy for the treatment of various diseases for which few known effective therapies exist. One strategy for combating disease processes has been to target the transcriptional process. Two approaches have been used to accomplish this: the use of antisense complimentary to the mRNA of interest and the use of ribozymes, a unique class of RNA molecules that not only store information but also process catalytic activity. Ribozymes are known to catalytically cleave specific target RNA, leading to its degradation, whereas antisense molecules inhibit translation by binding to mRNA sequences on a stoichiometric basis. More recently, small interfering RNA has been shown to inhibit target gene expression. The application of oligonuclotide technology, such as antisense, to regulate the transcription of disease-related genes in vivo has important therapeutic potential. Transfection of cis-element double-stranded oligodeoxynucleotides has been reported as a powerful tool in a new class of anti-gene strategies for molecular therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • DNA / metabolism
  • Genetic Therapy / methods*
  • Humans
  • Molecular Biology / methods*
  • Molecular Biology / trends
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / metabolism*
  • Oligonucleotides, Antisense / antagonists & inhibitors
  • Oligonucleotides, Antisense / genetics
  • Oligonucleotides, Antisense / therapeutic use*
  • Transcription Factors / antagonists & inhibitors
  • Transcription Factors / metabolism
  • Transcription Factors / therapeutic use*

Substances

  • NF-kappa B
  • Oligonucleotides, Antisense
  • Transcription Factors
  • DNA